Sector: Health Care
Director information for NEUROCRINE BIOSCIENCES INC
Board as disclosed in the proxy statement filed April 15, 2026. Titles and roles are as stated in that filing and may have changed since.
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Andrew Ratz, Ph.D. | Chief Technical Operations Officer | 58 | [] | [] | 2026 |
| Christine A. Poon | Director | 73 | ["Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Public Policy","Executive Leadership"] | ["Compensation","Science and Medical Technology"] | 2026 |
| Gary A. Lyons | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Risk Management Oversight","Human Capital Management"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 | ||
| George J. Morrow | Director | 74 | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Risk Management Oversight"] | ["Compensation","Science and Medical Technology"] | 2026 |
| Johanna Mercier | ["Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Human Capital Management"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 | ||
| Kevin C. Gorman, Ph.D. | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Science and Medicine","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Global Business Operations","Public Policy","Executive Leadership","Risk Management Oversight","Human Capital Management"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 | ||
| Kyle W. Gano, Ph.D. | Chief Executive Officer and Director | 53 | ["Financial Expertise / Capital Management and Allocation","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","Governance","Investor Relations","Executive Leadership","Human Capital Management"] | [] | 2026 |
| Leslie V. Norwalk | Director | 60 | ["Healthcare Industry","Biotech and Pharma Operations Expertise","Governance","Investor Relations","Public Policy","Executive Leadership"] | ["Nominating /Corporate Governance"] | 2026 |
| Richard F. Pops | Director | 64 | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Risk Management Oversight"] | ["Audit","Compensation"] | 2026 |
| Shalini Sharp | Director | 51 | ["Healthcare Industry","Governance","Investor Relations","Executive Leadership"] | ["Nominating /Corporate Governance"] | 2026 |
| Stephen A. Sherwin, M.D. | Director | 77 | ["Financial Expertise / Capital Management and Allocation","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","Governance","Investor Relations","Executive Leadership","Risk Management Oversight"] | ["Science and Medical Technology"] | 2026 |
| William H. Rastetter, Ph.D. | Board Chair; Chairman of the Board | 77 | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Public Policy","Executive Leadership","Risk Management Oversight"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 |
